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Streptococcus pneumoniae is the leading bacterial opportunistic
infection in HIV-infected individuals. Anti-retroviral treatment
(ART) of HIV-infected individuals reduces their risk of invasive
pneumococcal disease (IPD), however, it remains 20- to 40-fold
greater compared with age-matched general population.
This review summarizes the available published data on the
immunogenicity, safety and efficacy of pneumococcal
polysaccharide-protein conjugate vaccines (PCV) in HIV-
infected children and adults.
Several studies have demonstrated that PCV are safe in the
HIV-infected persons. Although PCV are immunogenic in HIV-
infected infants, the antibodies produced are functionally
impaired, there is possibly a lack or loss of anamnestic respon-
ses and immunity declines in later life… However, quantitative
and qualitative antibody responses to PCV in HIV-infected
infants are enhanced when vaccination occurs while on ART,
as well as if vaccination occurs when the CD4+ cell percent-
age is $ 25% and if the nadir CD4+ is . 15%. Although the
efficacy of PCV was lower, the vaccine preventable burden
of hospitalization for IPD and clinical pneumonia were 18-fold
and 9-fold greater, respectively, in HIV-infected children
compared with –uninfected children.
In HIV-infected adults, PCV vaccination induces more
durable and functional antibody responses in individuals on
ART at the time of vaccination than in ART-naive adults,
independently of baseline CD4+ cell count, although there
does not appear to be much benefit from a second-dose of
PCV. PCV has also been shown to reduce the risk of recurrent
IPD by 74% in HIV-infected adults not on ART, albeit, also with
subsequent decline in immunity and protection.
Introduction
Although less than one percent of the global under-5 y of age
population are HIV-infected,
1 these children account for 10.8%
of the approximately 870 000 annual deaths attributed to Strepto-
coccus pneumoniae, including 19.8% of pneumococcal deaths in
African children.
2 In the absence of antiretroviral treatment
(ART), S. pneumoniae is the leading bacterial opportunistic
infection with the risk of invasive pneumococcal disease (IPD)
being 40-fold greater in HIV-infected children.
3-5 In settings
such as Southern Africa where the prevalence of HIV in children
is less than 5% more than 65% of all IPD cases occur in HIV-
infected children.
3,5 Although the susceptibility to IPD is reduced
by 41% in HIV-infected children when treated with ART, the
risk nevertheless remains 21-fold (95% CI: 16 to 28) greater
compared with HIV-uninfected children.
3
Similarly HIV-infected adults have 10–300 times greater
susceptibility to IPD compared with HIV-uninfected indivi-
duals
6-10 and are at greater risk of recurrent IPD, with up to 25%
of individuals having an additional episode within the next
12 mo.
11,12 In HIV-infected adults the initiation of ART has been
associated with marked reductions in morbidity and mortality
from opportunistic infections, including 2- to 3-fold reductions
in the risk of IPD.
7,10 Nevertheless, in the US the incidence of
IPD in HIV-infected adults in the era of ART continued to be
approximately 35-fold greater than the general population.
10
The increased susceptibility of HIV-infected individuals to
pneumococcal disease in part relates to impairment of both
cell-mediated and humoral arms of the immune system. An
immunologic response to pneumococcal polysaccharides, a T-cell
independent type antigen, elicits production of serotype-specific
opsonic antibodies by B lymphocytes independent of T-lymphocyte
interaction.
13 Both T- and B-lymphocytes are decreased and
function impaired in HIV-infected individuals.
14,15 This results
in impaired quantitative and qualitative antibody responses to
natural infections and vaccination.
16,17 ART partially reconsti-
tutes the immune system of HIV-infected individuals, by
increasing B- and T-lymphocyte number and functionality.
However, deficiencies in humoral response because of depleted
or persistent defects in memory cell function persist after ART
initiation.
18
Vaccines available to protect against pneumococcal disease
include a 23-valent pneumococcal polysaccharide vaccines (PPV)
and polysaccharide-protein conjugate vaccines (PCV). PPV is
licensed for use in adults and children older than 2 y; and
particularly recommended for elderly persons and others with
specified underlying medical conditions.
19 In adults PPV reduces
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the risk of IPD and in some studies decreased the risk of
pneumonia.
20-22 However drawbacks of PPV vaccination include
that vaccine-induced antibody concentrations declined within
1–2 y post-vaccination.
23,24 In addition, PPV being processed as
a T-cell independent antigen does not prime for anamnestic
responses, is dominated by an IgM antibody response and may
result in hypo-responsiveness following subsequent doses of
vaccine.
25-27 PPV vaccination in children has also not consistently
being associated with a reduction in risk of nasopharyngeal
colonization with vaccine-serotype pneumococci.
28 In young
children, PPV is associated with poor immunogenicity, especially
for serotypes causing the majority of childhood pneumococcal
disease, due to immaturity of the T-cell independent immune
system in these children.
29
PCV induces a T-cell dependent immune response, which
matures while in utero, and has an improved immunogenicity
profile including in groups of individuals at high risk of
IPD.
30-32 Currently there are three licensed PCV formulation
for use in children and adolescents, including 7-valent [PCV7,
Prev(e)nar
TM; Pfizer Inc.], 10-valent (PCV10, Synflorix
TM;
GlaxoSmithKline) and 13-valent (Prevenar13
TM, Pfizer Inc.)
Previous reviews on PCV in adults has had limited emphasis
to HIV-infected individuals.
33,34 In addition the last review of
PCV in HIV-infected children was reported in 2008,
35 since
when there have been a number of new studies in HIV-infected
children. This review provides and updated analysis on the
safety, efficacy and immunogenicity of PCV in HIV-infected
individuals.
Methods
Data for this review were identified by doing a literature search
on PubMed using combinations of the following search terms:
“pneumococcus,”“ pneumococcal,”“ Streptococcus pneumoniae,”
“pneumococcal conjugate vaccine,”“ HIV,”“ conjugate vaccine,”
“immunogenicity,”“ efficacy” and “safety.” Only English language
studies were reviewed, no date restrictions were set and no
attempt at statistical analysis was undertaken.
Results
Measures of immunogenicity of PCV in children and adults.
The benchmark for measuring the immunogenicity of new
formulations of PCV is based on recommendations of a WHO
working group.
36 This includes the proportion of subjects who
attain serotype-specific antibody concentration of $ 0.35 mg/ml
measured by enzyme-linked immunosorbent assay (ELISA)
following a primary series of PCV for serotypes included in
PCV7. This threshold of antibody is a putative measure of
protection against IPD at a community-level in otherwise healthy
children but does not necessarily indicate protection at an
individual level nor is it serotype-specific.
36,37 The same threshold
of antibody, albeit not validated, has been used as a measure
of immunogenicity in HIV-infected children in more recent
studies.
16,38,39 Immunogenicity studies in adults and older child-
ren have primarily reported on the proportion of children with a
pre-defined increase in serotype-specific antibody concentration,
as the majority of older individuals will have had serotype-
specific antibody concentrations of $ 0.35 mg/ml through
naturally acquired antibody stimulation mainly from nasopha-
ryngeal colonization before vaccination.
The immunogenicity of PCV is also corroborated by the
geometric mean antibody concentrations (GMCs) and the func-
tionality of induced antibody measured by an opsonophagocytic
activity assay (OPA). The latter includes measuring the geometric
mean antibody titers (GMTs) and proportion of subjects with
measurable OPA activity (i.e., OPA $ 8). Studies indicate that
there may be a closer association using a serotype-specific thre-
shold of OPA $ 8 than antibody concentration $ 0.35 mg/ml as
a measure of protection against IPD at least for some serotypes
such as 6B and 19F.
16,40 Similarly, OPA measurements may be
more important in predicting potential efficacy for additional
serotypes included in newer formulation of PCV than antibody
concentration thresholds, as suggested by animal model studies of
PCV13 for serotype 3.
41 It is also important, particularly in the
context of HIV in children and other high-risk groups in whom
the risk of IPD may persist beyond that in the general population,
that the anamnestic responses induced by PCV be included in the
evaluation of the immunogenicity of the vaccines.
Immune responses to PCV vaccination in HIV-infected compared
with -uninfected children. Three different PCV formulations, all
containing CRM-197 (cross-reactive material) as the carrier pro-
tein, including PCV7 and experimental 5-valent PCV (PCV5)
and experimental 9-valent PCV (PCV9), have been evaluated for
immunogenicity in HIV-infected children.
16,38,39,42-49 In addition,
studies on the safety and immunogenicity of PCV10 (which
has protein-D, tetanus toxoid and diphtheria toxoid as carrier
proteins) and PCV13 (also containing CRM-197) are currently
underway with results expected in 2012/3. Direct comparisons
between the immunogenicity studies among HIV-infected
children are difficult since they varied in the dosing schedules
used, vaccination age, immunological endpoints analyzed, clinical
stage of HIV/AIDS disease and immunosuppression levels of the
participants and the proportion of participants on ART (Table 1).
Comparison of immune responses to PCV vaccination between
HIV-infected and uninfected children were reported in seven
studies.
16,38,39,43-45,48 Quantitative comparisons were made com-
paring the proportion of vaccinees who achieved either a pre-
defined serotype-specific antibody concentration
16,38,39,43,45 or a
pre-determined foldrise in antibody concentration from baseline
to post-vaccination.
44,48 In addition, qualitative responses using
OPA and long-term anamnestic effects have been evaluated in the
South African studies (Table 1).
16,39
PCV vaccination, together with the other routine infant
childhood vaccines, has been evaluated in two studies from South
Africa and one from US.
16,39,47 In the South African studies, PCV
was scheduled to be given at 6, 10 and 14 weeks of age with
immunogenicity measured one month after the three-dose
primary series of vaccine; Table 1.
16,39 The study by Nachman
et al. evaluated a three-dose schedule during infancy spaced two
months apart and a booster dose at 15 mo of age.
47 In the absence
of ART in African children, one month after a primary three-dose
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series of PCV9 (which included PCV7 serotypes and serotypes 1
and 5), the proportion of HIV-infected vaccinees with antibody
concentrations $ 0.35 mg/ml to vaccine serotypes ranged between
63 to 93% compared with 79 to 100% in HIV-uninfected
infants. This proportion was lower in HIV-infected compared
with –uninfected children for serotypes 1 (p = 0.03), 5 (p = 0.03),
18C (p = 0.03) and 23F (p = 0.04) (Fig.1). Similarly GMCs were
lower in HIV-infected children for all serotypes, albeit only
significantly so for serotypes 1 and 18C.
16 The differences in
response to PCV were, however, even more pronounced on
OPA for all three analyzed serotypes (6B, 19F and 23F). The
proportion of HIV-infected infants with OPA $ 8 was lower in
HIV-infected compared with uninfected infants for serotypes
6B (78% vs. 96%), 19F (46% vs. 91%) and 23F (57% vs. 93%)
(Fig.2). The proportion of HIV-infected subjects with OPA
titers $ 8 was more closely associated than the proportion with
antibody concentration of $ 0.35 mg/ml, in relation to 65%
efficacy against vaccine-serotype IPD observed in HIV-infected
children from the same population.
50 In addition, HIV-infected
children had lower GMTs and required higher concentration of
antibody for 50% killing activity on OPA. The higher antibody
concentration required for comparable OPA killing activity in
HIV-infected compared with uninfected children suggest func-
tional impairment of antibody in HIV-infected children. Thus,
the threshold of antibody concentration required for prevent-
ing IPD in HIV-infected children may be higher than the
$ 0.35 mg/ml putative threshold suggested for the general
population of children.
A follow-on study in the same setting, involved infants with
access to ART.
39 This included a group of HIV-infected infants
who were initiated on ART immediately upon being diagnosed as
having HIV infection at 4–12 weeks of age and another group
with CD4+ cell percentage $ 25% at the time of receipt of the
primary series of PCV, but who were only initiated on ART when
clinically or immunologic indicated as per previous WHO
treatment guidelines.
51 The immunogenicity of PCV, measured
Figure1. Proportion of responders with GMCs $ 0.35 mg/ml for the 7 serotypes included in PCV7. Data was derived from.
16,39 HIV+/PCV9/no ART:
HIV-infected children vaccinated with three PCV9 doses not on ART. HIV+/PCV7/delay ART: HIV-infected children vaccinated with three PCV7 doses
initiated on ART when clinically or immunologic indicated. HIV+/PCV7/ART: HIV-infected children vaccinated with three PCV7 doses on ART at the time of
vaccination. HIV-/PCV9: HIV-uninfected children vaccinated with three PCV9 doses. HIV-/PCV7: HIV-uninfected children vaccinated with three PCV7 doses.
Figure2. Proportion of responders with OPA titers $ 8 for serotypes 6B, 9V, 19F and 23F. Data was derived from
16 for serotypes 6B, 19F and 23F and
from
39 for serotypes 9V, 19F and 23F. HIV+/PCV9/no ART: HIV-infected children vaccinated with three PCV9 doses not on ART. HIV+/PCV7/delay ART:
HIV-infected children vaccinated with three PCV7 doses initiated on ART when clinically or immunologic indicated. HIV+/PCV7/ART: HIV-infected children
vaccinated with three PCV7 doses on ART at the time of vaccination. HIV-/PCV9: HIV-uninfected children vaccinated with three PCV9 doses. HIV-/PCV7:
HIV-uninfected children vaccinated with three PCV7 doses.
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by the proportion of vaccinees with antibody concentration of
$ 0.35 mg/ml, was similar between HIV-uninfected and both
groups of HIV-infected infants (Fig.1). These data corroborated
the findings from an earlier study by Nachman et al. in which
there was no difference in the GMCs in HIV-infected children,
71% of who were on protein-inhibitor based ART regimen,
compared with a historical control group of HIV-uninfected
infants.
47
The study by Nachman et al. has not reported on OPA
responses in those children. However, a significantly lower
proportion of HIV-infected African infants in whom ART was
delayed developed OPA titers of $ 8 to the three analyzed
serotypes, despite CD4+ cell percentage $ 25% at vaccination,
compared with HIV-uninfected infants or HIV-infected children
who were initiated on immediate ART (Fig.2). The poorer
qualitative immune response in the children in whom ART was
deferred was also associated with lower OPA GMTs and higher
concentration of antibody being required for 50% killing on
OPA than in HIV-uninfected children.
39 The response in HIV-
infected infants with CD4+ cell percentage $ 25% when
vaccinated but in whom ART was deferred was, however, better
relative to infants without any access to ART (Figs.1 and 2).
16
This comparison may, however, be biased as only children with
a CD4+ cell percentage $ 25% at time of vaccination were
included in the group in whom ART was deferred whereas the
CD4+ cell counts in the group without access to ART was not
evaluated. In addition, 17% of the children in whom ART was
deferred had been initiated on ART by the time of measuring
the immune response to the primary series of PCV.
39 These
infant studies indicate that PCV immunization is associated with
comparable immunogenicity as in HIV-uninfected infants when
undertaken if CD4+ cell percentage is $ 25% and children have
been initiated on early ART.
Other studies of PCV in HIV-infected children have mainly
involved those older than one year of age and have evaluated
different PCV schedules with or without PPV used as a booster/
supplementary dose. In two small studies evaluating an investiga-
tional PCV5, which included much higher serotype polysacchar-
ide concentration (10mg per serotype) than in currently licensed
formulations (2–4mg per serotype), the percentage of protocol-
defined responders, as per Table 1, although higher in HIV-
uninfected children was not significantly different from the
HIV-infected group at one month post-primary series.
45,48
However, the persistence of antibody was lower in HIV-infected
compared with—uninfected children one year after the initial
two-doses primary series of PCV.
45,48 The studies by King et al.
differed to that of Spoulou et al. in that the former reported
rapid and similar drop in antibody titers in HIV-infected
and—uninfected children, although antibody concentrations
were higher than at pre-vaccination.
43 In contrast, antibody levels
were sustained in HIV-uninfected children 12 mo after the
primary series in the study by Spoulou et al. compared with one
month post-primary series concentration, whereas HIV-infected
children experienced a decay in antibody concentrations to pre-
vaccination concentrations.
48 Differences in vaccine formulation
and study design could explain the observed differences in these
studies. Differences included that Spoulou et al. recruited older
children (mean age: 128 mo) most of them on ART (79%),
48
whereas the study by King et al. vaccinated younger children
(mean age: 12.9 mo).
43 The observation that a second dose
of PCV failed to induce any further increase in GMCs for
all serotypes among older HIV-infected children may suggest
the absence of PCV inducing anamnestic responses in these
children.
48 Lower antibody concentrations and greater magnitude
of decline in antibody concentration was also observed in ART-
naïve HIV-infected children compared with HIV-uninfected
children when measured five-years after the primary PCV series
during infancy.
38,46
PCV booster effect in HIV-infected children. Immunologic
memory in HIV-infected children previously primed with 2–3
doses of PCV was assessed by administrating a booster dose of
PCV at approximately 12 mo after primary series
47,48 or at 5 y
post-primary series.
46 When a booster dose of PCV was given at
15 mo of age after three primary doses during infancy which
included 71% of participants on ART and symptomatic and
asymptomatic children, anamnestic responses were detected.
47
This included higher serotype-specific antibody concentrations
post-booster compared with pre-booster concentration; and the
mean fold-change in antibody concentration being significantly
higher compared with the group who had previously received
placebo. Nevertheless PCV vaccinees experienced a significant
waning of serotype-specific GMCs at 24 mo of age, although they
remained above pre-immunization levels.
47 A booster dose of
PCV in older symptomatic HIV-infected children (median age
128 mo), 79% of whom were on ART, however, induced only a
modest increase in GMCs, indicating either absence of having
induced or failure to sustain an anamnestic response.
48
When HIV-infected children who received PCV9 (previous
vaccinees) or placebo (control group) during infancy were
vaccinated with one dose of PCV7 five years after the primary
three dose series during infancy in South Africa, an increase in
GMCs was observed for 6 of the 7 serotypes (all PCV7 serotypes
except 19F) compared with pre-booster GMCs in HIV-infected
children.
46 However, the magnitude in fold-change in concentra-
tions was greater for only three serotypes (serotypes 4, 6B and
14) among HIV-infected previous vaccinees compared with
previous placebo recipients. In addition, the proportion of
children with antibody concentrations $ 0.35 mg/ml was higher
for only two serotypes (serotypes 6B and 14) in previous PCV9-
vaccinees compared with controls when measured one month
after receipt of PCV.
46 Furthermore, irrespective of previous
priming with PCV during infancy, post-booster GMCs and
functional antibody activity were higher in HIV-uninfected
than—infected children. These observations also demonstrated
impairment in anamnestic immune responses in HIV-infected
children. The study was not, however, able to determine whether
the HIV-infected children had failed to develop immunologic
memory after primary immunization or whether there was a
subsequent loss of anamnestic responses with the HIV/AIDS
disease progression.
46
Association of HIV/AIDS disease stage and PCV immune response
in children. Most of the studies stratified HIV-infected children
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accordingly to clinical stage of AIDS or level of immuno-
suppression based on CD4+ cell measures. HIV-infected children
in the absence of ART with CDC clinical category-C AIDS had
lower GMCs to five (serotypes 5, 9V, 14, 18C and 23F) of the
nine PCV9 serotypes, compared with children who were CDC
clinical category N/A following completion of the primary series
of PCV9.
16 A multicenter study in the US with HIV-infected
children receiving ART, studied children aged 2–19 y who
received two doses of PCV7 followed by one PPV dose eight
weeks apart. This study demonstrated that higher antibody con-
centration at baseline, higher CD4+ cell percentage at vaccination,
higher nadir CD4+ percentage, lower HIV-viral loads, longer
duration of current ART regimen and younger age were predictors
of better immune response in HIV-infected children.
42 In
particular, children vaccinated early in the course of their HIV
illness, including when the CD4+ cell percentage was $ 25% at
its nadir and at the time of vaccination, had the greatest anti-
body increase in relation to prior antibody concentration after
each dose of vaccine. In addition, antibody concentrations
remained high in this group of children two years later. Con-
versely, immunization of children when both the nadir and time
of vaccination CD4+ cell percentage was , 15%, showed poor
antibody responses to both doses of PCV and the PPV. This study
also identified a significant positive association between anti-
body concentration and the duration of the ART regimen.
42
These results support the importance of ART in lymphocyte
reconstitution and the subsequent effect thereof on immuno-
genicity of PCV.
Other trials were less able to identify differences in response
rates to PCV based on CD4+ cell count, immune status before
ART or clinical AIDS stage.
43-45,47,49 In two of these studies a
substantial proportion of children were, however, also taking
ART.
47,49
Efficacy of PCV in HIV-infected children. The efficacy of
PCV has only been evaluated in HIV-infected children in a
randomized placebo-controlled trial in South Africa. This study
evaluated an investigational PCV9, which included serotypes 1
and 5 and was otherwise identical to PCV7.
50 The nine serotypes
included in PCV9 covered 83–91% of invasive disease causing
serotypes among HIV-infected children prior to the study.
9,35
PCV was found to be efficacious in preventing vaccine serotype-
specific IPD in HIV-infected infants, who were not on ART. The
vaccine efficacy, following 2.3 y of follow-up, against IPD in
HIV-infected was 65% (95% CI: 24 to 86) and lower than
observed in HIV-uninfected children (83%; 95% CI: 39 to 97).
50
However, because of the 40-fold greater burden of IPD pre-
existent in HIV-infected children,
4 despite the lower vaccine
efficacy, there was an 18-fold greater reduction in the burden
of vaccine-serotype IPD prevented in HIV-infected compared
with uninfected children (570 vs. 32 per 100,000 children
vaccinated, respectively).
50
PCV vaccination was also associated with non-significant
reductions in overall mortality (6%; p . 0.05) and reduction in
radiologic confirmed pneumonia (13%; 95% CI: -7 to 29).
50 The
lack of efficacy against the endpoint of radiologic confirmed
pneumonia may, however, have been confounded in that this
non-specific endpoint used as a surrogate for “pneumococcal
pneumonia” may have had even less specificity in HIV-infected
compared with -uninfected children.
52 This was corroborated in
part by subsequent, post hoc analysis, in which using different
criteria to define pneumonia revealed a 15% (95% CI: 5 to 24)
reduction in all-cause clinical pneumonia and 59% (95% CI: 1
to 83) reduction in vaccine-serotype bacteremic pneumonia in
HIV-infected children.
53 Furthermore, the low sensitivity of
blood cultures in the diagnosis of pneumococcal pneumonia,
even in HIV-infected children, was evident in that the vaccine-
attributable rate reduction was 5.3-fold greater for all-cause
clinical pneumonia (2,573 cases per 100,000 child-years
prevented) compared with bacteremic pneumococcal pneumonia
(483 per 100,000 child-years episodes).
53 Similarly to that
observed for IPD, there was 9-fold greater reduction of all-cause
clinical pneumonia in HIV-infected children compared with
uninfected children after 2.3 y of follow-up.
50,53 The South
African study, through using PCV vaccination as a probe, also
identified the important role of pneumococcal co-infection as a
precipitating cause of hospitalization for respiratory viral and
Mycobacterium tuberculosis associated pneumonia in HIV-infected
children.
54,55
At 5 y of follow-up in the South African study, in the absence
of a booster dose of PCV or ART access, vaccine efficacy against
IPD in HIV-infected children dropped from the initial 65%
estimate at 2.3 y of age to 39% (95% CI: -8 to 65). In HIV-
uninfected children, efficacy of a three-dose primary series of PCV
against IPD remained unchanged at 5 y post-vaccination (78%;
95% CI: 34 to 93) compared with at 2.3 y (83%).
38 Despite this,
the vaccine-attributable rate reduction in IPD, irrespective of
serotype, in HIV-infected children (2,250 per 100,000 child-years
prevented) was 59-fold greater compared with HIV-uninfected
children (38 per 100,000 child-years prevented) by five years of
age. The efficacy of PCV9 against any serotype IPD was, however,
greater in HIV-infected children (46%) than in HIV-uninfected
children (35%), mainly due to the cross-protection afforded by
the PCV9 against serotype 6A.
38 All these data emphasize the
need for sustained protection against IPD in HIV-infected
children well beyond the first two years of life, which is when
most disease occurs in HIV-uninfected children. Consequently,
determination of anamnestic responses and persistence thereof are
important measures when evaluating the immunogenicity of PCV
in HIV-infected and possibly other high risk groups of children.
Safety of PCV in HIV-infected children. Five studies from the
US or South Africa explored the safety of PCV in HIV-infected
children.
42,44,45,47,50 In all the studies PCV was well tolerated and
in the studies including a placebo arm, no significant differences
in local or systemic reactions between placebo and PCV recipients
were observed.
45,47 Nachman et al. however reported more
frequent severe signs and symptoms among PCV recipients than
placebo, and these included diarrhea, rash, fever and anemia.
47 In
the South African study a higher rate of asthma was reported
among PCV9 recipients, however no stratification by HIV-status
was done for asthma rate. In addition, the 5-y follow-up period of
this study revealed a lower CD4+ cell percentage, as well as a
similar trend in mean CD4+ counts, in previous PCV recipients
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compared with past placebo recipients.
38 The clinical significance
of the lower CD4+ cell count, in the absence of receiving ART,
among previous PCV recipients in HIV-infected children remains
to be explored.
Pneumoccocal polysaccharide vaccination in HIV-infected
adults. Immunization with a single dose of PPV is recommended
for HIV-infected adults and adolescents as soon as possible
after diagnosis of HIV infection and who have a CD4+ cell count
$ 200 cells/ml.
56-58 PPV vaccination of older HIV-infected
children and adults has been associated with poor or modest
immunogenicity.
44,59,60 Even in HIV-infected adults on ART,
PPV elicited only modest increases in functional antibody and
in serotype-specific antibody concentrations, with antibody
responses being lower than in healthy controls.
61-63 The use of
PPV in African HIV-infected adults is controversial. A rando-
mized placebo-controlled trial in Uganda reported an increase
in pneumonia in the six-month period following PPV vaccina-
tion of HIV-infected adults not on ART,
60 albeit subsequently
suggesting a 16% reduction in all-cause mortality.
64 A recent
meta-analysis by Pedersen et al., indicated marked heterogeneity
in results on the efficacy of PPV against varying pneumococcal
disease syndromes in HIV-infected adults and did not demon-
strate any overall benefit.
65 The effectiveness of PPV in HIV-
infected adults, and discrepant efficacy results between studies,
may be associated with HIV viral load and correspondingly
ART status at the time of vaccination.
60,61,64,66,67 Teshale et al.
suggested that PPV related protection against pneumonia was
only evident in individuals with HIV viral load of , 100,000
copies/ml irrespective of CD4+ immunologic categorization.
68
Several studies have also shown that HIV-infected persons with
CD4+ cell counts , 500 cells/ml have impaired antibody
responses against several pneumococcal serotypes compared with
less immunocompromized HIV-infected persons or healthy
controls.
59,69
In less immunocompromized HIV-infected individuals, the
rate of antibody decline after PPV vaccination is comparable
to healthy controls. However, since HIV-infected individuals
have lower post-vaccination antibody concentrations, their anti-
body concentrations may diminish to below the estimated pro-
tective levels sooner than in HIV-uninfected adults.
23,70 As there
are no immunologic correlates of clinical protection against IPD
for adults, immunogenicity studies in adults have used the
same threshold ($ 0.35mg/ml) suggested for infants or higher
thresholds such as 1mg/ml, or the fold increase in antibody
concentration as immunologic endpoints when measuring the
immunogenicity of PCV. In addition, some studies have also
evaluated OPA responses.
Immunogenicity of PCV in HIV-infected adults. Table 2
summarizes the studies in which the immunogenicity and safety
of PCV has been evaluated in HIV-infected adults, aimed at
showing better potential than that conferred by PPV. To our
knowledge only one published study reported on clinical efficacy
of PCV vaccination in HIV-infected adults.
80 Several other studies
have, however, explored the serotype-specific immune responses
induced by PCV in adults with HIV.
69-79 Direct comparisons
between studies were confounded in that some used PCV alone
while other studies evaluated PCV in combination with PPV.
Studies also varied in the definition of measuring immune
responses, including the use of endpoints such as antibody
concentration expressed as GMCs, functional antibody levels
determined by OPA or avidity experiments and percentage of
responders (fold rise in post-vaccination antibody titers compared
with pre-vaccination) (Table 2). Two of the studies
69,70 presented
in Table 2 measured serum antibody titers by ELISA without
the currently recommended step of absorption with hetero-
logous pneumococcal polysaccharides 22F to improve serotype-
specific antibody specificity by inhibiting non-serotype specific
antibodies.
81
Studies that included a PCV-vaccinated HIV-uninfected group
as a control consistently detected a better antibody response in
HIV-uninfected than in HIV-infected individuals.
69,70,74,75,77 An
exception was the study by Chen, et al. where no difference in
GMCs for serotype 4 between the HIV-infected and uninfected
groups was detected at any timepoint, although only two
serotypes (4 and 14) were evaluated.
75
PCV immunogenicity vs. PPV in HIV-infected adults. A 4-arm
randomized trial with two doses of vaccines and/or placebo
administered to HIV-infected subjects 8 weeks apart (PCV7-
PCV7, PCV7-PPV23, placebo-PPV23 and placebo-placebo
groups) reported that antibody concentration and OPA
16 weeks after the initial vaccine dose were significantly higher
in the groups that received PCV compared with the group that
just received PPV for four of the five serotypes tested.
71 In
addition, there was a trend for higher proportion of responders
in the PCV-vaccinated group compared with the placebo-PPV
group with regard to obtaining more than 2-fold rise in GMCs
or 4-fold rise in OPA titers, albeit only significant for serotype 4.
A second PCV dose eight weeks after the first PCV7 dose did not
produced any further increase in antibody response.
71
Another study with a shorter dosing schedule (4 weeks between
vaccinations) but a longer follow-up period also found that the
response profile was better in the arm that received a PCV dose
followed by PPV 4 weeks later compared with the PPV-only
group.
73 These differences were, however, only evident after
the PCV group had received their PPV dose. Superiority of the
PCV-PPV arm considering both antibody levels and percentage
of responders was sustained at least until 24 weeks post-first
dose.
73
PCV vaccination of HIV-infected adults previously vaccinated
with PPV 3–8 y earlier transiently induced a better immune
response than PPV revaccination at 60 d post-vaccination.
77
However, at 180 d post-vaccination there was no difference
in antibody concentration between the two groups, indicating
that PCV vaccination provided little additional immunologic
benefit compared with PPV re-vaccination.
77 While PCV elicited
good antibody responses and in several studies higher than
that induced by PPV at particular timepoints these differences
were not markedly different. A study in Spain where PPV was
given alone or 4 weeks after PCV did not find any difference
between the two vaccination arms in serotype-specific anti-
body avidity and proportion of responders (defined as a 2-fold
rise in antibody titers and antibody concentration of at least
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1mg/ml), except for serotype 23F, in the PCV-group at 8 weeks
post-PCV.
76
PCV priming of the immune system in HIV-infected adults.
Vaccination with PCV followed by PPV allowed several studies
to explore the possibility of priming of the immune system
by PCV. Even though the interval between vaccines appears
to play a role, evidences of inducing anamnestic responses are
sparse.
70,71,73,75,76,78 In a study in Denmark where HIV-infected
adults were immunized twice 3 mo apart with double the
standard dose of PCV7 and received PPV nine months after the
first-PCV7 dose, GMCs did not increase at one month post-
PPV compared with one month post-second PCV dose levels.
However, OPA titers were higher at one month post-PPV for
three (i.e., 14, 19F and 23F) of the four serotypes assessed.
78
Since this study did not include a PPV-only arm, it is not clear
if the increase in OPA titers post-PPV were due to anamnestic
responses induced through priming with PCV.
78 Lesprit et al.,
however, reported that PPV given four weeks after PCV resulted
in better immune response measured four weeks later, com-
pared with HIV-infected adults only vaccinated with PPV. This
included higher percentage of responders (defined as a 2-fold
rise in GMCs from baseline and GMC $1ug/mL) and higher
GMCs for six (i.e., 4, 9V, 14, 18C, 19F and 23F) of the
serotypes common to PCV7 and PPV at four weeks post-PPV.
The higher antibody concentration in PCV7 recipients was
maintained at least until 20 weeks post-PPV for four serotypes,
although the percentages of responders dropped in each group.
73
As evident by the results of these studies the dosing schedule
and timing of vaccination of HIV-infected adults with
pneumococcal vaccines still needs further investigation however
a schedule with a dose of PCV followed by PPV seems the
most adequate in possibly enabling induction of anamnestic
immune responses by PCV as well as by expanding serotype
coverage of those serotypes included in the 23-valent PPV but
absent in PCV.
Factors associated with PCV response in HIV-infected adults.
Pneumococcal vaccines induced antibody responses are probably
dependent on CD4+ cell function. Most of the studies that
included HIV-infected persons with CD4+ cell counts less than
200 cells/ml, observed a lower antibody response to PCV com-
pared with persons with counts higher than 200 cells/ml analyzing
either absolute antibody concentrations
70,72 or fold rise in anti-
body levels.
70 However it has been suggested that the association
between CD4+ cell count and antibody response is mainly due
to a direct association between CD4+ cell count and baseline
antibody concentration.
72 When searching for factors associated
with PCV-specific immunologic response CD4+ cell count,
virologic status or receipt of ART at initiation of vaccine series
were not significantly associated with differences in antibody
concentration and OPA titers during follow-up until 60–112
d.
71,77 However, in one study after administration of two doses
of double-strength PCV7 three months apart, HIV-infected
adults on ART achieved a more durable antibody response, of
higher magnitude than ART-naive individuals, independent of
pre-vaccination CD4+ cell count.
78 Both ART-experienced and
ART-naïve subjects achieved comparable initial responses to
PCV, but after a period of 9 mo post-first PCV dose significant
differences were apparent in the proportion of vaccine responders
(defined as a 2-fold rise in GMCs from baseline to $ 1 ug/mL for
at least five serotypes) in the two ART groups.
78
In search for a more immunogenic pneumococcal vaccine for
use in HIV-infected adults the addition of an adjuvant was
explored by Sogaard et al.
79 This study evaluated the inclusion
of a toll-like receptor agonist and vaccine adjuvant (CPG7909)
to PCV7 and PPV. In this study the proportion of vaccine
high responders (defined as a 2-fold increase in antibody levels to
. 1 mg/mL for at least five serotypes) was higher in the CPG7909
group than among controls at 4, 9 and 10 mo. OPA titers were
also elevated in the CPG7909 group. The enhanced production
of antibodies by CPG7909 was, however, negatively correlated
with HIV viral load indicating that this strategy was unlikely to
benefit HIV-infected individuals with detectable HIV-viremia.
Even though vaccination with the addition of CPG7909 was
generally well tolerated, mild systemic and injection site reactions
to first and/or second PCV dose were more common in the
CGP7909 group than in the control group. After PPV immuni-
zation influenza-like symptoms were more common in the
CPG7909 group.
Studies that report on HIV viral loads after vaccination, have
not observed significant increases above pre-vaccination levels
after one or two PCV doses.
71,77
Clinical efficacy of PCV in HIV-infected adults. Although
immunogenicity studies provide evidence of relative response
between PCV and PPV, the absence of serologic correlates of
protection against disease in HIV-infected individuals and in
adults, requires demonstration of the efficacy of PCV against
pneumococcal disease in HIV-infected adults. To date, there are
no head-to-head randomized trials which compared the efficacy
of PCV to that of PPV in HIV-infected adults. There have,
however, been two separate double-blind, randomized, placebo-
controlled clinical trials, one comparing PPV efficacy with placebo
against pneumonia as discussed earlier and the other comparing
PCV7 efficacy with placebo for protecting against recurrent
vaccine-serotype IPD.
60,80
The efficacy of PCV7 was assessed in Malawi from 2003
to 2007 in HIV-infected adolescents and adults (15 y of age or
older) who had recovered from an IPD episode.
80 The primary
end point was a further episode of IPD caused by PCV7 serotypes
or serotype 6A. Two doses of PCV7 or placebo were given
4 weeks apart and subjects were followed up for a mean of 1.2 y.
Overall 496 subjects were enrolled, 88% being HIV-infected and
of those 13% were on ART at baseline. Twenty-four (36%) of all
new IPD episodes (n = 67) were PCV7 or 6A serotype and the
unadjusted vaccine efficacy was 74% (95% CI: 30 to 90) with a
hazard ratio of 0.26 (95% CI: 0.10 to 0.70). Vaccine efficacy,
however, decreased from 85% in the first year post-vaccination to
25% thereafter. Protection against IPD was also evident in the
subgroup of participants with CD4+ cell counts , 200 cells/ml,
with a vaccine efficacy of 86% (95% CI: 41 to 97).
80 The overall
protection against IPD, irrespective of serotype, had a hazard ratio
of 0.72 (95% CI: 0.42 to 1.25). In addition, no overall effect
was observed in mortality between PCV7 recipients (29%) and
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placebo recipients [25%; adjusted hazard ratio: 1.24 (95% CI: 0.9
to 1.8)]. CD4+ cell count at enrolment was the strongest risk
factor for IPD in this study in a multivariable analysis. Compared
with subjects with CD4+ cell counts higher than 500cells/ml,
patients with CD4+ cell counts , 200 cells/ml had seven times
higher risk of a recurrent IPD episode. A lower CD4+ cell count
was also associated with death and pneumonia from any cause.
80
The study was not powered to investigate the interaction between
PCV and the use of ART. The greater diversity of serotypes
causing IPD in adults may, however, require formulations of PCV
with broadened serotype coverage than that included in the
current formulation of PCV targeted primarily at serotypes highly
prevalent in children.
Safety of PCV in HIV-infected adults. The safety and
tolerability of PCV administration in HIV-infected adults was
comparable to PPV vaccination, both vaccines being generally
well tolerated. Individuals who received PCV tended to reported
more local pain at injection site than PPV recipients in two
studies.
69,71 The frequency of other reactions including fever,
redness, swelling and tenderness were similar in the two vaccine
arms. The majority of reaction reported were self-limited. In
the PCV efficacy trial in Malawi, serious adverse events were
significantly more common in the placebo arm.
80 In the
revaccination study by Crum-Cianflone et al., one HIV-infected
PCV-vaccinated subject developed encephalitis 41 d after
revaccination which was attributed as possibly being related to
the vaccine.
77
PCV and indirect protection. In addition to the direct
effect of PCV, vaccination of young children has also been
associated with reduction of vaccine-serotype IPD in the general
population of unvaccinated individuals.
82,83 This reduction is
attributed to the effectiveness of PCV in reducing the risk of
nasopharyngeal acquisition of the targeted vaccine serotypes in
vaccinated children, who are traditionally considered the most
important source of transmission of pneumococci within com-
munities.
84 In addition to indirect effect observed in the general
US population,
85 widespread childhood PCV7 immunization
has also been temporally associated with reduction in vaccine-
serotype IPD in HIV-infected adults in US (91%).
86 The
decline in overall IPD has, however, been offset by an increase
in non-vaccine serotype IPD (28%) in this population with a
net overall reduction of IPD being 41%.
86,87 In the analysis
by Cohen et al. from 2004–2007, the incidence of IPD (cases
per 100,000) in HIV-infected adults remained 40-times higher
than among HIV-uninfected adults.
86 Although these data
indicate the potential of childhood PCV immunization benefiting
HIV-infected individuals from developing IPD, these findings
need further exploration in African settings where there may
be a greater diversity of serotypes associated with IPD com-
pared with in the US. In addition, lower levels of childhood
immunization coverage, differing dosing schedules and more
limited catch-up campaigns of immunizing older children and
possible differences in the dynamics of pneumococcal trans-
mission in developing countries may affect the indirect potent-
ial of vaccines in some settings with a high prevalence of
HIV-infection.
Conclusions
Studies on PCV demonstrate promise for directly and indirectly
protecting HIV-infected individuals against developing IPD and
pneumonia. PCV vaccination of HIV-infected children on ART,
particularly when immunologic competent when immunized,
indicate similar quantitative and qualitative antibody responses as
in HIV-uninfected children. However, the immunogenicity,
efficacy and durability of protection of HIV-infected children
not receiving ART indicates the need for possible booster doses of
PCV later in life, albeit preferably after they been initiated on
antiretroviral treatment. The frequency and timing of these
additional booster doses in HIV-infected children independently
of ART usage still needs to be determined to improve vaccine
effectiveness. Furthermore long-term anamnestic responses to
PCV are yet to be established in HIV-infected children vaccinated
while receiving ART.
The introduction of PCV into national children immunization
programs in settings with high HIV burden should be careful
designed and should include catch-up campaigns targeting HIV-
infected children not vaccinated during infancy to optimize the
prevention of pneumococcal disease.
Although some studies in adults are inconsistent on the
immunologic advantage of PCV over PPV, PCV has nevertheless
been associated with protection against vaccine serotype IPD in
high risk HIV-infected adults even largely in the absence of ART.
However the limited serotype coverage of PCV (seven to 13
serotypes) requires HIV-infected individuals to also receive PPV
in addition to PCV, to expand the coverage of potential disease
causing serotypes.
The greatest benefit of PCV immunization programs against
IPD may, however, be realized through the indirect effect of
childhood vaccination against adult disease. This needs to be
further explored, including for some of the newer serotypes
included in PCV13 (e.g., 1, 3, 5 and 7F) and not PCV7 which
may differ in the dynamics of transmission within communities.
The indirect effect of PCV in protecting adults in settings with a
high prevalence of HIV, particularly in Africa, needs further study
since significant differences exist between these settings and
developed countries regarding immunization practices and vaccine
coverage. The magnitude of the herd effect was not confirmed on
a small study in South Africa, a country with a high prevalence of
adult HIV.
88 The divergences with the South African study can be
due to the absence of a booster dose of PCV and to an overall
PCV coverage of , 20%. It is known that herd immunity efficacy
is affected by serotype distribution, actual proportion of children
vaccinated and also by social factors.
In addition, the effect of possible replacement disease due to
non-vaccine serotypes negating any decrease in vaccine-serotype
disease also requires evaluation in settings with high HIV burden
after PCV introduction.
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